KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic results from a Phase 1 Single Ascending Dose Study

Autor:	Lily Li, Edward Duckworth, Michael D. Smith, Andreas Maetzel, Louise J. Rushbrooke, Sally L. Hampton, Gian Marco De Donatis, Nivetha Murugesan, Edward P. Feener, Christopher M. Yea, Rachel M. Morten
Rok vydání:	2019
Předmět:	Plasma kallikrein inhibitor On demand treatment Pharmacokinetics business.industry Pharmacodynamics Immunology Hereditary angioedema Immunology and Allergy Medicine Pharmacology business medicine.disease
Zdroj:	Journal of Allergy and Clinical Immunology. 143:AB39
ISSN:	0091-6749
DOI:	10.1016/j.jaci.2018.12.118
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::17a3eb5a276cf13efee6943be9f6c0e3 https://doi.org/10.1016/j.jaci.2018.12.118 Zobrazit plný text záznamu Full Text from ScienceDirect